Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.

Ryuji YasumatsuTakahiro WakasakiKazuki HashimotoKoichiro NakashimaTomomi ManakoMasahiko TauraMioko MatsuoTakashi Nakagawa

Published in: Head & neck (2019)

Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.

Keyphrases

squamous cell carcinoma
small cell lung cancer
combination therapy
open label
clinical trial
double blind